Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-05 10:55 am Sale | 13D | NGM BIOPHARMACEUTICALS INC NGM | COLUMN GROUP L P | 1,000 100% | -22,078,509 (-100.00%) | View |
| 2024-02-26 5:16 pm Unchanged | 13D | NGM BIOPHARMACEUTICALS INC NGM | COLUMN GROUP L P | 22,079,509 26.7% | 0 (Unchanged) | View |
| 2024-02-14 6:12 pm Sale | 13G | NGM BIOPHARMACEUTICALS INC NGM | EcoR1 Capital LLC | 2,385,873 2.9% | -4,049,645 (-62.93%) | View |
| 2024-02-13 5:09 pm Sale | 13G | NGM BIOPHARMACEUTICALS INC NGM | VANGUARD GROUP INC | 2,770,574 3.35% | -1,718,575 (-38.28%) | View |
| 2023-12-29 4:05 pm Purchase | 13D | NGM BIOPHARMACEUTICALS INC NGM | COLUMN GROUP L P | 22,079,509 26.7% | 1,094,533 (+5.22%) | View |
| 2023-10-06 2:34 pm Sale | 13G | NGM BIOPHARMACEUTICALS INC NGM | BlackRock Inc. BLK | 3,839,879 4.6% | -318,764 (-7.67%) | View |
| 2023-02-13 12:57 pm Sale | 13G | NGM BIOPHARMACEUTICALS INC NGM | Rho Ventures V L.P. | 430,783 0.5% | -3,372,487 (-88.67%) | View |
| 2023-02-09 11:27 am Purchase | 13G | NGM BIOPHARMACEUTICALS INC NGM | VANGUARD GROUP INC | 4,489,149 5.49% | 4,489,149 (New Position) | View |
| 2023-02-03 4:27 pm Purchase | 13G | NGM BIOPHARMACEUTICALS INC NGM | BlackRock Inc. BLK | 4,158,643 5.1% | 4,158,643 (New Position) | View |
| 2022-10-28 5:34 pm Purchase | 13G | NGM BIOPHARMACEUTICALS INC NGM | EcoR1 Capital LLC | 6,435,518 8% | 6,435,518 (New Position) | View |
| 2022-06-10 4:14 pm Purchase | 13D | NGM BIOPHARMACEUTICALS INC NGM | COLUMN GROUP L P | 20,984,976 26.5% | 1,951,343 (+10.25%) | View |
| 2022-02-03 5:23 pm Purchase | 13D | NGM BIOPHARMACEUTICALS INC NGM | COLUMN GROUP L P | 19,033,633 24.5% | 1,378,422 (+7.81%) | View |
| 2021-02-16 2:53 pm Purchase | 13G | NGM BIOPHARMACEUTICALS INC NGM | Rho Ventures V L.P. | 3,803,270 5.5% | 12,604 (+0.33%) | View |
| 2021-02-12 5:25 pm Purchase | 13G | NGM BIOPHARMACEUTICALS INC NGM | Rho Ventures V L.P. | 3,790,666 5.5% | 6,000 (+0.16%) | View |
| 2020-11-20 4:36 pm Sale | 13G | NGM BIOPHARMACEUTICALS INC NGM | Topspin Fund L.P. | 3,320,498 4.8% | -1,512,836 (-31.30%) | View |
| 2020-04-02 06:07 am Purchase | 13D | NGM BIOPHARMACEUTICALS INC NGM | COLUMN GROUP L P | 17,655,211 26% | 1,111,314 (+6.72%) | View |
| 2020-02-11 4:58 pm Purchase | 13G | NGM BIOPHARMACEUTICALS INC NGM | Rho Ventures V L.P. | 3,784,666 5.7% | 3,784,666 (New Position) | View |
| 2019-11-26 09:39 am Purchase | 13G | NGM BIOPHARMACEUTICALS INC NGM | Topspin Fund L.P. | 4,833,334 7.4% | 4,833,334 (New Position) | View |
| 2019-10-18 4:11 pm Purchase | 13D | NGM BIOPHARMACEUTICALS INC NGM | COLUMN GROUP L P | 16,543,897 25.1% | 810,883 (+5.15%) | View |
| 2019-05-17 4:31 pm Purchase | 13D | NGM BIOPHARMACEUTICALS INC NGM | COLUMN GROUP L P | 15,733,014 23.8% | 98,923 (+0.63%) | View |